Skip to main content
. Author manuscript; available in PMC: 2012 Apr 4.
Published in final edited form as: Mol Pharm. 2011 Feb 15;8(2):621–628. doi: 10.1021/mp100446t

Figure 4.

Figure 4

(A) Representative decay-corrected whole-body coronal microPET images of mice bearing MDA-MB-435 breast cancer at 2.5 h after intravenous injection of 18F-FMISO (1.11 MBq/mouse) on days 0, 1, 3, 7 and 14 after the treatment was initiated. The tumors are indicated by arrows. Increased tumor uptake of 18F-FMISO was observed on day 1 and day 3 but was restored to the baseline level on day 7. Upper panel: control; Lower panel: VEGF121/rGel treatment. (B) Quantitative microPET region of interest analysis of tumor uptake for 18F-FMISO. (* p < 0.05, ** p < 0.01)